shares of renalytix were trading higher in thursdays afterhours session following news the us food and drug administration has granted de novo marketing authorization for the kidneyintelxdkd prognostic test at 647 pm et the companys stock had risen 30 to 270 a share the stock finished the days regular session with a 35 gain closing at 207 a share renalytix said the authorization affirms kidneyintelx as a firstinclass artificial intelligence enabled prognostic testing platform to guide care management for adults with type 2 diabetes and early stage chronic diabetic kidney disease de novo authorization provides a marketing pathway for novel medical devices the fda said